Help appealing denials for this first biologic treatment for IgA nephropathy.

Appeal Your Voyxact Denial

Get access to this breakthrough APRIL-blocking treatment for IgA nephropathy.

Understanding Your Voyxact (sibeprenlimab) Denial

Voyxact (sibeprenlimab) is the first biologic drug approved for reducing proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. IgA nephropathy is a serious kidney disease that can lead to kidney failure. If your nephrologist prescribed Voyxact, you have strong grounds for appeal.

Common Reasons for Denial

! Prior authorization required
! Biopsy-proven IgAN not documented
! Proteinuria level not high enough
! Must try ACE inhibitors/ARBs first
! Specialty tier drug not covered
! Accelerated approval status concerns

How We Help

We help you document your biopsy results, proteinuria levels, eGFR, prior treatments, and risk of disease progression to demonstrate medical necessity for Voyxact.

Start your Voyxact appeal — it takes about 3 minutes.

Some Types of Evidence We Can Use For Supporting Your Appeal

✓ Sibeprenlimab blocks APRIL, reducing the production of pathogenic IgA antibodies that cause kidney damage in IgA nephropathy.

✓ Clinical trials demonstrated significant reduction in proteinuria and stabilization of kidney function with sibeprenlimab treatment.

✓ IgA nephropathy is the most common primary glomerulonephritis worldwide and leads to kidney failure in 20-40% of patients over 20 years.

✓ Reducing proteinuria is associated with slower disease progression and reduced risk of kidney failure in IgA nephropathy.

Patient Assistance & Copay Programs

These programs may help reduce your costs while you appeal:

Otsuka Patient Services (VOYXACT)

Eligible patients may pay as little as $0 through the VOYXACT Copay Program. Bridge program available for coverage delays. Call 833-VOYXACT (869-9228).

Eligibility requirements and program terms may change. Please verify current details directly with each organization.

Patient Advocacy & Support Organizations

These organizations provide education, support, and advocacy for patients:

IgA Nephropathy Foundation of America

Foundation dedicated to IgA nephropathy awareness, research, and patient support.

National Kidney Foundation

Leading kidney health organization with advocacy and patient resources.

Frequently Asked Questions

Key documentation includes kidney biopsy confirming IgA nephropathy, recent proteinuria levels (typically 1 g/day or higher), eGFR results, and records showing you've been on ACE inhibitors or ARBs for an adequate period.

This typically means having significant proteinuria (1 g/day or more) despite treatment with renin-angiotensin system blockers, which indicates higher risk of progressing to kidney failure.

Ready to Fight Your Voyxact (sibeprenlimab) Denial?

Our free AI-powered tool will help you generate a compelling appeal letter in minutes.

Start Your Appeal Chat with AI Assistant

Disclaimer: Fight Health Insurance is not affiliated with, endorsed by, or partnered with any pharmaceutical manufacturer, healthcare provider, medical device company, or patient assistance program, including Otsuka Pharmaceutical. All information provided is for educational and informational purposes only and does not constitute medical or legal advice. Please consult with your healthcare provider regarding treatment options and with your insurance company regarding coverage decisions.